• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

富马酸替诺福韦二吡呋酯与甲磺酸奈非那韦之间不存在药代动力学药物相互作用。

Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.

作者信息

Boffito Marta, Pozniak Anton, Kearney Brian P, Higgs Christopher, Mathias Anita, Zhong Lijie, Shah Jaymin

机构信息

PK Research, St. Stephen's Centre, Chelsea and Westminster Hospital, London, UK.

出版信息

Antimicrob Agents Chemother. 2005 Oct;49(10):4386-9. doi: 10.1128/AAC.49.10.4386-4389.2005.

DOI:10.1128/AAC.49.10.4386-4389.2005
PMID:16189129
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1251521/
Abstract

A study explored the pharmacokinetics of tenofovir (300 mg administered once daily) and nelfinavir (1,250 mg twice daily) when coadministered in 29 healthy volunteers. Tenofovir, nelfinavir, and M8 pharmacokinetics was unaltered when tenofovir and nelfinavir were coadministered, and tenofovir administration did not affect the M8/nelfinavir area under the concentration-versus-time curve over the dosing interval (AUC(tau)) ratio. No interaction between tenofovir and nelfinavir was observed.

摘要

一项研究探讨了29名健康志愿者同时服用替诺福韦（每日一次，每次300毫克）和奈非那韦（每日两次，每次1250毫克）时的药代动力学。当替诺福韦和奈非那韦同时给药时，替诺福韦、奈非那韦和M8的药代动力学未发生改变，且替诺福韦给药不影响给药间隔期间浓度-时间曲线下面积（AUC(tau)）的M8/奈非那韦比值。未观察到替诺福韦和奈非那韦之间存在相互作用。

相似文献

1
Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.富马酸替诺福韦二吡呋酯与甲磺酸奈非那韦之间不存在药代动力学药物相互作用。
Antimicrob Agents Chemother. 2005 Oct;49(10):4386-9. doi: 10.1128/AAC.49.10.4386-4389.2005.
2
The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.奈非那韦与替诺福韦联合用药在HIV感染患者中的稳态药代动力学。
Antivir Ther. 2005;10(2):349-55.
3
Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.BILR 355/r 与恩曲他滨/替诺福韦酯富马酸联合给药可增加恩曲他滨和替诺福韦的暴露量：一项随机、开放标签、前瞻性研究。
Basic Clin Pharmacol Toxicol. 2011 Mar;108(3):163-70. doi: 10.1111/j.1742-7843.2010.00636.x. Epub 2010 Oct 27.
4
Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.恩曲他滨和替诺福韦酯富马酸盐单独及联合给药在健康志愿者中的稳态药代动力学。
J Clin Pharmacol. 2007 Jun;47(6):751-9. doi: 10.1177/0091270007300951.
5
Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.奈非那韦和M8在HIV感染患者中的细胞内及血浆药代动力学：与P-糖蛋白表达的关系
Antivir Ther. 2004 Feb;9(1):77-84.
6
Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.福沙那韦/利托那韦加替诺福韦不影响安普那韦的药代动力学：替诺福韦无影响。
AIDS. 2007 Jun 19;21(10):1368-70. doi: 10.1097/QAD.0b013e32810c8ce2.
7
Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine.富马酸替诺福韦二吡呋酯与去羟肌苷之间的药物相互作用及药物与食物相互作用。
J Clin Pharmacol. 2005 Dec;45(12):1360-7. doi: 10.1177/0091270005281351.
8
Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.在健康受试者中，利巴韦林与替诺福韦之间不存在具有临床相关性的药代动力学相互作用。
J Clin Pharmacol. 2006 May;46(5):559-66. doi: 10.1177/0091270006287704.
9
Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.富马酸替诺福韦二吡呋酯与利福平联用在健康志愿者中的药代动力学研究
Antimicrob Agents Chemother. 2005 Feb;49(2):680-4. doi: 10.1128/AAC.49.2.680-684.2005.
10
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.在HIV阳性患者中，将阿扎那韦（未联用利托那韦）与富马酸替诺福韦二吡呋酯联合使用时，从每日一次400毫克转换为每日两次200毫克的药代动力学。
Antivir Ther. 2011;16(4):499-504. doi: 10.3851/IMP1802.

引用本文的文献

1
Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate.富马酸替诺福韦二吡呋酯在妊娠和产后妇女中应用的群体药代动力学研究。
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.02168-20.
2
Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.在对富马酸替诺福韦二吡呋酯具有良好依从性的成年人中停止治疗后，替诺福韦的血浆药代动力学和尿排泄。
Int J Infect Dis. 2020 Aug;97:365-370. doi: 10.1016/j.ijid.2020.06.037. Epub 2020 Jun 14.
3
The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects.阿哌沙班对健康受试者中地高辛和阿替洛尔药代动力学的影响。
Clin Pharmacol. 2017 Feb 23;9:19-28. doi: 10.2147/CPAA.S115687. eCollection 2017.
4
Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition.使用草药对处于健康转型期的非洲人群的药物基因组学影响。
Pharmaceuticals (Basel). 2015 Sep 21;8(3):637-63. doi: 10.3390/ph8030637.
5
The role of drug transporters in the kidney: lessons from tenofovir.药物转运体在肾脏中的作用：来自替诺福韦的启示。
Front Pharmacol. 2014 Nov 11;5:248. doi: 10.3389/fphar.2014.00248. eCollection 2014.
6
Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.妊娠对替诺福韦药代动力学的影响：一项纳入 186 名女性的群体研究。
Antimicrob Agents Chemother. 2012 Feb;56(2):857-62. doi: 10.1128/AAC.05244-11. Epub 2011 Nov 28.
7
Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss.替诺福韦治疗原代成骨细胞改变基因表达谱：对骨密度丢失的影响。
Biochem Biophys Res Commun. 2010 Mar 26;394(1):48-53. doi: 10.1016/j.bbrc.2010.02.080. Epub 2010 Feb 18.
8
Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts.替诺福韦暴露于原代破骨细胞后 Gnas、Got2 和 Snord32a 的下调。
Biochem Biophys Res Commun. 2010 Jan 15;391(3):1324-9. doi: 10.1016/j.bbrc.2009.12.039. Epub 2009 Dec 21.
9
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.福沙那韦或阿扎那韦每日一次联合100毫克利托那韦，加用替诺福韦/恩曲他滨，用于初治HIV感染：ALERT研究48周结果
AIDS Res Ther. 2008 Mar 28;5:5. doi: 10.1186/1742-6405-5-5.
10
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.人类免疫缺陷病毒蛋白酶抑制剂对替诺福韦酯体外肠道吸收的影响。
Antimicrob Agents Chemother. 2007 Oct;51(10):3498-504. doi: 10.1128/AAC.00671-07. Epub 2007 Jul 30.

本文引用的文献

1
The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.奈非那韦与替诺福韦联合用药在HIV感染患者中的稳态药代动力学。
Antivir Ther. 2005;10(2):349-55.
2
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.在HIV-1感染受试者中，沙奎那韦硬胶囊/利托那韦（每日两次，每次1000/100毫克）与富马酸替诺福韦二吡呋酯联用时的药代动力学。
Br J Clin Pharmacol. 2005 Jan;59(1):38-42. doi: 10.1111/j.1365-2125.2004.02240.x.
3
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.初治抗逆转录病毒患者中替诺福韦酯与司他夫定联合治疗的疗效和安全性：一项为期3年的随机试验
JAMA. 2004 Jul 14;292(2):191-201. doi: 10.1001/jama.292.2.191.
4
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.替诺福韦酯治疗核苷类耐药HIV-1感染的随机试验。
Ann Intern Med. 2003 Sep 2;139(5 Pt 1):313-20. doi: 10.7326/0003-4819-139-5_part_1-200309020-00006.
5
Therapeutic drug monitoring in HIV infection: current status and future directions.HIV感染中的治疗药物监测：现状与未来方向。
AIDS. 2002 Mar;16 Suppl 1:S5-37. doi: 10.1097/00002030-200203001-00002.
6
Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon*.替诺福韦二磷酸是大鼠DNA聚合酶α、δ和ε*的不良底物及弱抑制剂。
Antimicrob Agents Chemother. 2002 May;46(5):1610-3. doi: 10.1128/AAC.46.5.1610-1613.2002.